FTC OKs Novartis' $1.5B Fougera Buy With Divestitures

Law360, New York (July 16, 2012, 7:38 PM ET) -- The Federal Trade Commission on Monday approved Novartis AG's $1.5 billion purchase of dermatology treatment specialist Fougera Holdings Inc. from several private equity funds, after the drugmaker agreed to give up its marketing rights to four topical skin care treatments to alleviate competition concerns.

The FTC voted 5-0 to accept Novartis' proposed settlement, which resolves the agency's complaint that the proposed merger would reduce competition by cutting the limited number of suppliers for four skin treatments, including generic versions of scalp psoriasis treatment calcipotriene. Under the...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required